NAV

Cirtuvivint

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cirtuvivint
DrugBank Accession Number
DB17269
Background

Cirtuvivint is a first-in-class CDC-like kinase (CLK) inhibitor.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 427.512
Monoisotopic: 427.212058453
Chemical Formula
C24H25N7O
Synonyms
  • 4-pyridinecarboxamide, 2-(4-methyl-1-piperazinyl)-n-(6-(1-methyl-1h-pyrazol-4-yl)-3-isoquinolinyl)-
  • CDC-like kinase inhibitor of the Wnt Pathway
External IDs
  • SM 08502
  • SM-08502
  • SM08502
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7T1PY32ZPH
CAS number
2143917-62-6
InChI Key
BQWWOBKMDWACGC-UHFFFAOYSA-N
InChI
InChI=1S/C24H25N7O/c1-29-7-9-31(10-8-29)23-13-18(5-6-25-23)24(32)28-22-12-20-11-17(3-4-19(20)14-26-22)21-15-27-30(2)16-21/h3-6,11-16H,7-10H2,1-2H3,(H,26,28,32)
IUPAC Name
N-[6-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-yl]-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide
SMILES
CN1C=C(C=N1)C1=CC2=C(C=C1)C=NC(NC(=O)C1=CC=NC(=C1)N1CCN(C)CC1)=C2

References

General References
Not Available
ChemSpider
115006926
BindingDB
293424
ChEMBL
CHEMBL4784318

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdult Solid Tumor1
1Active Not RecruitingTreatmentCastration Resistant Prostate Cancer / Colorectal Cancer / Non-Small Cell Lung Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0591 mg/mLALOGPS
logP2.81ALOGPS
logP2.84Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)14.39Chemaxon
pKa (Strongest Basic)7.39Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area79.18 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity138.87 m3·mol-1Chemaxon
Polarizability48.6 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at November 30, 2022 22:17 / Updated at July 18, 2023 22:58